AKBA - Akebia Ther - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

AKBA is currently covered by 1 analysts with an average price target of $7.7. This is a potential upside of $4.41 (134.04%) from yesterday's end of day stock price of $3.29.

Akebia Ther's activity chart (see below) currently has 76 price targets and 73 ratings on display. The stock rating distribution of AKBA is 7.69% HOLD and 92.31% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 49.29% with an average time for these price targets to be met of 295.09 days.

Highest price target for AKBA is $7.5, Lowest price target is $7.5, average price target is $7.5.

Most recent stock forecast was given by ED ARCE from HC WAINWRIGHT on 04-Apr-2025. First documented stock forecast 14-May-2015.

Currently out of the existing stock ratings of AKBA, 1 are a HOLD (7.69%), 12 are a BUY (92.31%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$7.5

$4.49 (149.17%)

$7.5

4 months 10 days ago
(04-Apr-2025)

14/29 (48.28%)

$5.73 (323.73%)

327

Buy

$4

$0.99 (32.89%)

$2

2 years 2 months 14 days ago
(31-May-2023)

2/12 (16.67%)

$2.96 (284.62%)

753

Buy

$1

$-1.14 (-53.27%)

$8

3 years 4 months 13 days ago
(01-Apr-2022)

1/2 (50%)

$0.33 (49.25%)

311

Buy

$6

3 years 4 months 14 days ago
(31-Mar-2022)

0/3 (0%)

$3.28 (120.59%)

Hold

$2

$-1.01 (-33.55%)

$6

3 years 4 months 14 days ago
(31-Mar-2022)

3/11 (27.27%)

$1.28 (177.78%)

467

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is AKBA (Akebia Ther) average time for price targets to be met?

On average it took 295.09 days on average for the stock forecasts to be realized with a an average price target met ratio 49.29

Which analyst has the current highest performing score on AKBA (Akebia Ther) with a proven track record?

DIFEI YANG

Which analyst has the most public recommendations on AKBA (Akebia Ther)?

Difei Yang has 22 price targets and 20 ratings on AKBA

Which analyst is the currently most bullish on AKBA (Akebia Ther)?

Jonathan Aschoff with highest potential upside - $24.86

Which analyst is the currently most reserved on AKBA (Akebia Ther)?

Alethia Young with lowest potential downside - -$1.14

Akebia Ther in the News

Akebia GAAP EPS of $0.00 beats by $0.02, revenue of $62.47M beats by $15.23M

* Akebia press release [https://seekingalpha.com/pr/20192771-akebia-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business] (NASDAQ:AKBA [https://seekingalpha.com/symbol/AKBA]): Q2 GAAP EPS of $0.00 beats by $0.02. * Revenue of $62.47M (+43.1% Y/Y) beats by $15.23M. MORE ON AKEBIA * Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 [https://seekingalpha.com/article/4793211-akebia-therapeutics-stock-is-trading-at-fair-value-amid-robust-drug-adoption-into-2026-hold] * Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before...

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Akebia Therapeutics, Inc. Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?